Catenacci, D. V. T., Kang, Y.-K., Uronis, H. E., Lee, K.-W., Ng, M. C. H., Enzinger, P. C., … Park, H. (2023). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma. ONCOLOGY-NEW YORK, 37(4), 175–184.

Catenacci, Daniel V. T., Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, et al. “Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma.” ONCOLOGY-NEW YORK 37, no. 4 (2023): 175–84.

Catenacci DVT, Kang Y-K, Uronis HE, Lee K-W, Ng MCH, Enzinger PC, et al. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma. ONCOLOGY-NEW YORK. 2023;37(4):175–84.

Catenacci, Daniel V. T., et al. “Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma.” ONCOLOGY-NEW YORK, vol. 37, no. 4, 2023, pp. 175–84.

Catenacci DVT, Kang Y-K, Uronis HE, Lee K-W, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Cheul S, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song E-K, Chee CE, Chao Y, Kim S, Oh D-Y, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma. ONCOLOGY-NEW YORK. 2023;37(4):175–184.